FTC Requires Divestiture of Generic Drugs to Prevent Higher Costs in Aurobindo-Lannett Acquisition

The Federal Trade Commission has mandated that Aurobindo Pharma Limited divest four generic drug products as a condition for its $250 million acquisition of Lannett Company Inc. This action aims to prevent potential anti-competitive effects that could lead to higher drug costs for patients.